Search

Your search keyword '"Mijin Jeon"' showing total 2 results
Start Over Author "Mijin Jeon" Journal acta haematologica
2 results on '"Mijin Jeon"'

1. Blast Percentage of Bone Marrow Aspirate on Day 14 of Induction Chemotherapy Predicts Adult Acute Lymphoblastic Leukemia Treatment Outcomes

Author

Seongsoo Jang, Miee Seol, Hyun-Sook Chi, Je-Hwan Lee, Han-Seung Park, Dae-Young Kim, Kyoo-Hyung Lee, Young-Uk Cho, Young-Shin Lee, Eun-Ji Choi, Jung-Hee Lee, Mijin Jeon, Young-Ah Kang, and Chan-Jeoung Park

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Multivariate analysis, Biopsy, Treatment outcome, Immunophenotyping, 03 medical and health sciences, 0302 clinical medicine, Bone marrow aspirate, Bone Marrow, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Transplantation, Homologous, Medicine, Aged, Aged, 80 and over, CD20, biology, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Induction chemotherapy, Bone Marrow Examination, Induction Chemotherapy, Hematology, General Medicine, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Combined Modality Therapy, Survival Analysis, Treatment Outcome, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cytogenetic Analysis, Adult Acute Lymphoblastic Leukemia, biology.protein, Female, Bone marrow, Neoplasm Grading, business, Biomarkers, 030215 immunology
Abstract

The prognosis of adult acute lymphoblastic leukemia is much worse than that of pediatric acute lymphoblastic leukemia, even when patients achieve complete remission. Early response to treatment can be an important alternative indicator of treatment outcomes. The purpose of our current study was to identify the prognostic value of the blast percentage of the induction interim bone marrow, which might predict relapse-free survival and overall survival in patients with adult acute lymphoblastic leukemia. A retrospective analysis was performed on 80 adult patients diagnosed with Philadelphia chromosome-negative acute lymphoblastic leukemia from 1994 to 2011. Complete remission was observed in 75 (93.8%) patients after induction chemotherapy. On multivariate analysis, a reduction of blasts to a level of 5% or less in the induction interim bone marrow and CD20 positivity were significant prognostic predictors of relapse-free survival (hazard ratio, HR = 2.88, p = 0.006, and HR = 2.67, p = 0.010) and overall survival (HR = 2.10, p = 0.033, and HR = 2.39, p = 0.013). The blast percentage of the induction interim bone marrow may be a useful prognostic factor to predict outcome.

Published
2018

2. Up-front allogeneic hematopoietic cell transplantation in acute myeloid leukemia arising from the myelodysplastic syndrome

Author

Yunsuk Choi, Ahrang Jung, Jung-Hee Lee, Young Hoon Park, Miee Seol, Young-Ah Kang, Dae-Young Kim, Young Shin Lee, Je-Hwan Lee, Mijin Jeon, Sung-Doo Kim, Jae Seok Lee, and Kyoo Hyung Lee

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Myeloid, Adolescent, medicine.medical_treatment, Hematopoietic stem cell transplantation, Disease-Free Survival, Young Adult, hemic and lymphatic diseases, Internal medicine, Medicine, Secondary Acute Myeloid Leukemia, Humans, Survival rate, Aged, Retrospective Studies, business.industry, Remission Induction, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Induction chemotherapy, Hematology, General Medicine, Middle Aged, medicine.disease, Allografts, Transplantation, Survival Rate, Leukemia, Leukemia, Myeloid, Acute, surgical procedures, operative, medicine.anatomical_structure, Myelodysplastic Syndromes, Female, business
Abstract

In patients with secondary acute myeloid leukemia (s-AML) arising from the myelodysplastic syndrome (MDS), treatment outcome is unsatisfactory. We compared up-front allogeneic hematopoietic cell transplantation (HCT) to induction chemotherapy (IC) as an initial treatment in patients with s-AML arising from MDS. This retrospective study included 85 patients who were diagnosed with s-AML arising from MDS; 11 patients proceeded to up-front HCT without IC (HCT group) and 74 received IC (IC group) as an initial treatment for s-AML, 28 of whom subsequently underwent HCT. In the IC group, 41.9% achieved complete remission (CR) compared to 81.8% in the HCT group (p = 0.013). The HCT group showed a significantly longer event-free survival (EFS) than the IC group (median 29.2 vs. 5.2 months, p = 0.042). Overall survival of the HCT group was higher than that of the IC group, but the difference was not statistically significant (median 34.6 vs. 7.6 months, p = 0.149). After adjustment for other clinical factors, outcome in the HCT group was significantly better than in the IC group in terms of CR rate (hazard ratio, HR, 11.195; p = 0.007) and EFS (HR, 0.384; p = 0.029). Up-front HCT is a viable option in s-AML arising from MDS if an appropriate donor is available. © 2014 S. Karger AG, Basel

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results